|
|
Article: In Spite Of Strong Growth to Date, Sales of Eloxatin for Colorectal Cancer Are Expected To Slow Down Significantly In the Coming Years As Generic Oxaliplatin Begins To Enter the EU Markets.
- Article from:
- Business Wire
- Article date:
- November 15, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45259) has announced the addition of Pipeline/Commercial Insight: Colorectal Cancer - Shaping the Future Dynamics of Colorectal Cancer Management to their offering.
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.
Scope of this title: ...